Added to YB: 2025-11-11
Pitch date: 2025-11-07
NVO [bearish]
Novo Nordisk A/S
-2.9%
current return
Author Info
No bio for this author
Upgrade to Yellowbrick Premium to unlock investor returns. Upgrade to Yellowbrick Premium
Company Info
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products.
Market Cap
DKK 1.4T
Pitch Price
DKK 298.75
Price Target
N/A
Dividend
3.76%
EV/EBITDA
9.60
P/E
13.52
EV/Sales
4.81
Sector
Pharmaceuticals
Category
N/A
Show full summary:
Stocks Update 7/11/2025 - Novo Nordisk (NVO)
NVO (earnings): Q3 results disappointing with revenue/EBIT below expectations amid $9B restructuring. Ozempic/Wegovy growth slowing due to pricing pressure & US reimbursement concerns. Insulin franchise contracting. Guidance downgraded to single-digit growth 2025. Strong pipeline intact but margin expansion era ending.
Read full article (2 min)